Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis.

Vegter, Stefan; Tolley, Keith; Keith, Michael S; Postma, Maarten J

Vegter, Stefan; Tolley, Keith; Keith, Michael S; Postma, Maarten J.

Affiliation

Vegter S; Department of Pharmacy, Unit of PharmacoEpidemiology and PharmacoEconomics (PE(2)), University of Groningen, Groningen, The Netherlands. s.vegter@rug.nl

Value Health ; 14(6): 852-8, 2011.

Article in En | MEDLINE | ID: mdl-21914505

Subject(s)

Hyperphosphatemia/drug therapy; Kidney Failure, Chronic/therapy; Lanthanum/economics; Renal Dialysis; Cost-Benefit Analysis; Humans; Hyperphosphatemia/etiology; Kidney Failure, Chronic/complications; Lanthanum/therapeutic use; Models, Economic; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; State Medicine; United Kingdom

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Renal Dialysis / Hyperphosphatemia / Kidney Failure, Chronic / Lanthanum Type of study: Clinical_trials / Etiology_studies / Guideline / Health_economic_evaluation Limits: Humans Country/Region as subject: Europa Language: En Journal: Value Health Journal subject: FARMACOLOGIA Year: 2011 Type: Article Affiliation country: Netherlands

Fulltext

XML

PubMed Links

Search on Google